Literature DB >> 7036729

Body fluid homeostasis in congestive heart failure and cirrhosis with ascites.

K L Skorecki, B M Brenner.   

Abstract

The urinary excretion of salt and water in man is regulated by a variety of renal and extrarenal mechanisms that respond to changes in dietary sodium intake as well as to alterations in the holding capacity of the vascular and interstitial compartments. Changes in extracellular fluid volume are detected by volume sensors located in the intrathoracic vascular bed, the kidney and other organs. These sensing mechanisms gauge the adequacy of intravascular volume relative to capacitance at various sites within the circulation. Congestive heart failure and cirrhosis with ascites are two disease states of man in which a hemodynamic disturbance within a given circulatory subcompartment is perceived by these sensing mechanisms and results in renal sodium retention. While the primary disturbance in both of these conditions originates outside the kidney, a variety of renal effector mechanisms respond to the perceived circulatory disturbance and result in enhanced tubule reabsorption of salt and water. These effector mechanisms involve physical adjustments in renal microvascular hemodynamics, tubule fluid composition and flow rate and transtubular ion gradients. These in turn are partially regulated by a variety of neural and humoral pathways including the renin-angiotensin-aldosterone axis, prostaglandins, and kinins.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036729     DOI: 10.1016/0002-9343(82)90824-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

1.  Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis.

Authors:  F R Ibarra; C Afione; D Garzon; M Barontini; J C Santos; E Arrizurieta
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Pharmacodynamic and kinetic considerations on diuretics as a basis for differential therapy.

Authors:  H Knauf; E Mutschler
Journal:  Klin Wochenschr       Date:  1991-04-04

4.  Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion.

Authors:  H Knauf; E Wenk; J Schölmerich; K J Goerg; W Gerok; H G Leser; E Mutschler
Journal:  Klin Wochenschr       Date:  1990-06-05

5.  Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study.

Authors:  Javed Butler; Lampros Papadimitriou; Vasiliki Georgiopoulou; Hal Skopicki; Sandra Dunbar; Andreas Kalogeropoulos
Journal:  Circ Heart Fail       Date:  2015-05       Impact factor: 8.790

Review 6.  Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.

Authors:  G Hasenfuss; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

7.  Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.

Authors:  H Ring-Larsen; J H Henriksen; C Wilken; J Clausen; H Pals; N J Christensen
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-24

Review 8.  Physiological state tunes mesolimbic signaling: Lessons from sodium appetite and inspiration from Randall R. Sakai.

Authors:  Samantha M Fortin; Mitchell F Roitman
Journal:  Physiol Behav       Date:  2016-11-19

Review 9.  Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Diuretic therapy in congestive heart failure for the elderly patient.

Authors:  E T Carvalho Filho
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.